The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia
Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, discusses adverse events associated with BTK inhibitors (BTKis) in the treatment of Waldenström’s macroglobulinemia, with reference to his study comparing bendamustine and rituximab (BR) with ibrutinib in the frontline. He mentions atrial fibrillation and bleeding abnormalities as the main factors that lead to the discontinuation of BTKis. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
